- Home
- News
- micronesia
- injectable formulation
Injectable Formulation Articles & Analysis
9 news found
As the new academic year looms on the horizon, CD Formulation is ecstatic to announce a special Back to School Promotion 2024. Emphasizing its commitment to supporting educational and research institutions, the promotion offers up to 10% off on all their products and services. This timely initiative aims to facilitate ground-breaking research and innovation in pharmaceutical, cosmetic, and ...
CD Formulation is making waves in the pharmaceutical industry with its innovative drug delivery technologies. With a focus on sustained and controlled release formulations, as well as liquid, semi-solid, injectable, and nanoformulations, CD Formulation is at the forefront of the industry's efforts to enhance drug efficacy. One of CD Formulation's key technology platforms is its sustained ...
CD Formulation, a leading innovator in drug delivery technologies, has recently introduced a series of groundbreaking microneedle patch innovations that promise to revolutionize the way drugs are administered. Microneedle patches are a novel drug delivery system that utilizes tiny needles to painlessly penetrate the skin's outer layer and deliver medication directly into the bloodstream. This ...
As medicine continues to advance in this new era, drug delivery methods have been revolutionized to enhance patient comfort, improve treatment outcomes and ensure effective delivery of therapeutic compounds. CD Formulation, a leading pharmaceutical research and development company, has recently unveiled a series of cutting-edge technologies that will further revolutionize and redefine the realm ...
Since its launch, the pharmaceutical excipients provided by CD Formulation have gained significant popularity among customers worldwide. To enhance the search process, CD Formulation has recently reorganized its collection of pharmaceutical excipients and unveiled these changes on its website. With a focus on improving drug delivery systems and dosage forms, the company aims to offer innovative ...
Abstract: We previously reported the development of a novel formulation of an ultra-long-acting local anesthetic based on bupivacaine encapsulated in large multivesicular liposomes (Bupisomes) embedded in hydrogel. This formulation (Bupigel) prolonged bupivacaine release from the formulation in dissolution-like studies in vitro and analgesia in vivo in mouse, rat, and pig models. In this study we ...
12-Month Primary Endpoint Data Suggest OpRegen is Well Tolerated with an Acceptable Safety Profile Preliminary Evidence of Visual Function and Outer Retinal Structure Improvements Observed in Cohort 4 Patients with GA and Impaired Vision Data Reported at 2022 ARVO Meeting by Allen C. Ho, M.D., FACS Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage ...
Genentech Will Pay Lineage $50 Million Upfront Eligible to Receive a Total of $670 Million in Upfront and Milestone Payments Conference Call to Discuss Collaboration Planned for 8 a.m. ET Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), today announced that Lineage and its subsidiary, Cell Cure Neurosciences Ltd., have entered into an exclusive worldwide collaboration and ...
The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies TALENT is the world's first phase III clinical trial of the new long-acting HIV-1 fusion inhibitor, Aikening® (generic name: Albuvirtide [ABT]) in an all-Asian population TALENT ...